Ildong’s chronic hepatitis B treatment ‘Besivo Tab’ become 28th Korean new drug

Ildong Pharmaceutical(CEO Woong-Sup Yoon) acquired approval of ‘Besivo Tab(generic name: besifovir dipivoxil maleat),’ a new chronic hepatitis B treatment developed by on its own, from the Ministry of Health and Welfare.

Thus, ‘Besivo Tab’ not only became the 28^th Korean new drug, but will be recorded as the first chronic hepatitis B, nucleotide treatment developed by Korean technology for the...